Skip to main content
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery 4/2023

17.05.2023 | Other Articles

Colchicine in the Management of Oral Submucous Fibrosis: A Systematic Review, Meta-analysis, and GRADE-Based Assessment of Certainty of Evidence

verfasst von: Arpita Rai, Ansul Kumar, Priya Shree, Zeya ul Haque, Sneha Kumari, Satyendra Prasad Yadav, Simpy Amit Mahuli, Shoa Shamsi

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose: To study the efficacy of Colchicine in the management of Oral Sub mucous Fibrosis (OSMF) through systematic review and meta-analysis. Methods:An extensive literature search was conducted on databases such as PubMed, Cochrane Library database, LILACS, Google Scholar, CTRI, and Google search engine. The search comprises all articles published from 2013 to 2022. A total of 10 randomized control trial studies involving colchicine as one of the interventions were included. [CRD42022377674] Results:10 randomized control comprising 456 subjects were included. 3 studies are included in the meta-analysis comprising 90 subjects. All three studies show that there are significant differences between colchicine and other intervention regarding mouth opening and burning sensation. It indicates that Colchicine is significantly more effective in the reduction of burning sensation than other interventions used as a control in OSMF. Conclusion: The evidence generated through this systemic review and meta-analysis suggest that the use of an oral form of colchicine is an effective measure in the management of OSMF, especially the subjective symptom such as burning sensation where as it is not found to be much effective in case of mouth opening. If colchicine is used as co drug along with conventional injection therapy better will the result. However there is marked diversity among the studies reviewed; therefore, the results of this review should be interpreted very carefully.
Literatur
1.
Zurück zum Zitat Tilakaratne WM, Klinikowski MF, Saku T, PetersT J, Warnakulasuriya S (2006) Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42:561–568CrossRefPubMed Tilakaratne WM, Klinikowski MF, Saku T, PetersT J, Warnakulasuriya S (2006) Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42:561–568CrossRefPubMed
2.
Zurück zum Zitat Wang YY, Tail YH, Wang WC, Chen CY, Kao YH, Chen YK et al (2014) Malignant transformation in 5071 southern taiwanese patients with potentially malignant oral mucosal disorders. BMC Oral Health 14:99CrossRefPubMedPubMedCentral Wang YY, Tail YH, Wang WC, Chen CY, Kao YH, Chen YK et al (2014) Malignant transformation in 5071 southern taiwanese patients with potentially malignant oral mucosal disorders. BMC Oral Health 14:99CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Pindborg JJ, Mehta FS (1995) Etiology of oral submucous fibrosis with special reference to the role of areca nut chewing. J Oral Pathol Med 24:145–152CrossRefPubMed Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Pindborg JJ, Mehta FS (1995) Etiology of oral submucous fibrosis with special reference to the role of areca nut chewing. J Oral Pathol Med 24:145–152CrossRefPubMed
4.
Zurück zum Zitat More BC, Shah HP, Rao RN, Pawar KR (2015) Oral submucous fibrosis: an overview with evidence based management.International journal of oral health sciences and advances. ;3 More BC, Shah HP, Rao RN, Pawar KR (2015) Oral submucous fibrosis: an overview with evidence based management.International journal of oral health sciences and advances. ;3
5.
Zurück zum Zitat Diegelmann RF, Peterkofsky B (1972) Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci U S A 69:892–896CrossRefPubMedPubMedCentral Diegelmann RF, Peterkofsky B (1972) Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci U S A 69:892–896CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Wallace SI, Bernstein D, Diamond H (1967) Diagnostic value of the colchicine therapeutic trial. JAMA 199:525–528CrossRefPubMed Wallace SI, Bernstein D, Diamond H (1967) Diagnostic value of the colchicine therapeutic trial. JAMA 199:525–528CrossRefPubMed
7.
Zurück zum Zitat Daga D, Singh RK, Pal US, Gurung T, Gangwar S (2017) Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis. Natl J Maxillofac Surg 8:50–54CrossRefPubMedPubMedCentral Daga D, Singh RK, Pal US, Gurung T, Gangwar S (2017) Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis. Natl J Maxillofac Surg 8:50–54CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Khande K, Pathak A (2021) Effectiveness of oral colchicine with intralesional hyaluronidase and triamcinolone acetonide in patients with OSMF. J Adv Med Dent Sci Res 9:41–44 Khande K, Pathak A (2021) Effectiveness of oral colchicine with intralesional hyaluronidase and triamcinolone acetonide in patients with OSMF. J Adv Med Dent Sci Res 9:41–44
9.
Zurück zum Zitat Krishnamoorthy B, Khan M (2013) Management of oral submucous fibrosis by two different drug regimens: a comparative study. Dent Res J 10:527–532 Krishnamoorthy B, Khan M (2013) Management of oral submucous fibrosis by two different drug regimens: a comparative study. Dent Res J 10:527–532
10.
Zurück zum Zitat Sheth M, Makadia N, Patel N, Patel M, Patel DK, Patel B (2017) Evaluation of two different treatment modalities for the management of oral Submucous fibrosis: a relative report and analysis. J Adv Med Dent Scie Res 5:8–10 Sheth M, Makadia N, Patel N, Patel M, Patel DK, Patel B (2017) Evaluation of two different treatment modalities for the management of oral Submucous fibrosis: a relative report and analysis. J Adv Med Dent Scie Res 5:8–10
11.
Zurück zum Zitat Mounika M, Manne SV, Kannan RK, Beeraka N, Sarath SS, Saikiran PV (2021) Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study. J Indian Acad Oral Med Radiol 33:236–241CrossRef Mounika M, Manne SV, Kannan RK, Beeraka N, Sarath SS, Saikiran PV (2021) Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study. J Indian Acad Oral Med Radiol 33:236–241CrossRef
12.
Zurück zum Zitat Neupane GP, Rai M, Rathor RS, Bhargava VK, Mahat AK, Dhami DB (2016) Comparative study of Intralesional Dexamethasone Plus hyaluronidase & oral colchicine in patients with oral Submucous Fibrosis. J Nepalgunj Med Coll 14:60–65CrossRef Neupane GP, Rai M, Rathor RS, Bhargava VK, Mahat AK, Dhami DB (2016) Comparative study of Intralesional Dexamethasone Plus hyaluronidase & oral colchicine in patients with oral Submucous Fibrosis. J Nepalgunj Med Coll 14:60–65CrossRef
13.
Zurück zum Zitat Dr Nishant, Dr Bhagwat S Sharma and Dr Neha Rajput. Comparison between two different treatment modality for the management of oral submucous fibrosis.International Journal of Recent Scientific Research Dr Nishant, Dr Bhagwat S Sharma and Dr Neha Rajput. Comparison between two different treatment modality for the management of oral submucous fibrosis.International Journal of Recent Scientific Research
14.
Zurück zum Zitat Sidana JS, Gaba R, Agarwal U, Kaur J (2022) To determine the efficacy of colchicine as a monotherapy in oral Submucous fibrosis (OSMF) patients.International Journal of Health Sciences. ;6 Sidana JS, Gaba R, Agarwal U, Kaur J (2022) To determine the efficacy of colchicine as a monotherapy in oral Submucous fibrosis (OSMF) patients.International Journal of Health Sciences. ;6
15.
Zurück zum Zitat Kumar V, Kumar A, Jamal A, Sinha M (2021) Comparison of management of OSMF Patients. Annals of International Medical and Dental Research 7:365–370 Kumar V, Kumar A, Jamal A, Sinha M (2021) Comparison of management of OSMF Patients. Annals of International Medical and Dental Research 7:365–370
16.
Zurück zum Zitat Mostafa M G, Khan J A, Ahmed S, Kamruzzaman M, Islam M R, Rahman M A et al Comparison between Efficacy of Combined Use of Hyaluronidise and Triamcinolone versus Hyaluronidise, Triamcinolone Acetonide and oral colchicine in the treatment of oral Submucous Fibrosis.Mymensingh Med J; 30:79–84 Mostafa M G, Khan J A, Ahmed S, Kamruzzaman M, Islam M R, Rahman M A et al Comparison between Efficacy of Combined Use of Hyaluronidise and Triamcinolone versus Hyaluronidise, Triamcinolone Acetonide and oral colchicine in the treatment of oral Submucous Fibrosis.Mymensingh Med J; 30:79–84
17.
18.
Zurück zum Zitat Sodhi S, Sodhi JS, Khambete N, Kumar R, Marthala M, Sodhi NK (2014) Expression of tumor necrosis factor and its correlation with severity of oral submucous fibrosis: a casecontrol study. Oral Surg Oral Med Oral Pathol Oral Radiol 117:704–708CrossRefPubMed Sodhi S, Sodhi JS, Khambete N, Kumar R, Marthala M, Sodhi NK (2014) Expression of tumor necrosis factor and its correlation with severity of oral submucous fibrosis: a casecontrol study. Oral Surg Oral Med Oral Pathol Oral Radiol 117:704–708CrossRefPubMed
Metadaten
Titel
Colchicine in the Management of Oral Submucous Fibrosis: A Systematic Review, Meta-analysis, and GRADE-Based Assessment of Certainty of Evidence
verfasst von
Arpita Rai
Ansul Kumar
Priya Shree
Zeya ul Haque
Sneha Kumari
Satyendra Prasad Yadav
Simpy Amit Mahuli
Shoa Shamsi
Publikationsdatum
17.05.2023
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe 4/2023
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-023-03876-1

Weitere Artikel der Ausgabe 4/2023

Indian Journal of Otolaryngology and Head & Neck Surgery 4/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.